Kinam Hong

    Partner, Crossover Strategy

    Kinam joined us in January 2017 as a partner driving Sofinnova's later-stage, crossover investment strategy. Prior to joining Sofinnova Partners, Kinam was a co-manager of the Exane Equinox fund, a global healthcare fund backing later-stage, public biotechnology companies. Before that, he spent 10 years as an investor and analyst covering the biotechnology sector, including at Citigroup Investment Research, where he specialized in small- and mid-cap biotechnology companies.

    Kinam was attracted by Sofinnova Crossover's hands-on approach to later-stage investing. "It's different when you are an active investor with a larger ownership," he says. "You have the ability to make a bigger impact. Sometimes you need to be in the room.”

    Prior to his investment career, Kinam worked in new product development at Sanofi, the multinational pharmaceutical company, where he held various roles in product development, business development and strategic marketing, working on infectious diseases and oncology licensing deals, and on the company’s China strategy.

    Kinam is a physician and scientist, holding degrees in molecular biology/biochemistry and medicine from the University of Florida. He also holds a CFA (Chartered Financial Analyst) and MBA from INSEAD (France).

    Kinam enjoys combining the medicine and investing aspects of his role, which "has the potential to make an impact on patients and makes every day interesting."

    "Sometimes you need to have a significant stake in a company and be in the board room to really drive some of the strategy and the changes it may need."

    Sector

    Biopharmaceuticals

    Related companies

    Welcome to our new website – a fresh look that represents a new SofinnovaFind out more